Original language | English (US) |
---|---|
Pages (from-to) | 1195-1197 |
Number of pages | 3 |
Journal | Leukemia |
Volume | 25 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2011 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma. / Kapoor, P.; Kumar, S.; Mandrekar, S. J. et al.
In: Leukemia, Vol. 25, No. 7, 07.2011, p. 1195-1197.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Efficacy of thalidomide-or lenalidomide-based therapy in proliferative multiple myeloma
AU - Kapoor, P.
AU - Kumar, S.
AU - Mandrekar, S. J.
AU - Laumann, K. M.
AU - Dispenzieri, A.
AU - Lacy, M. Q.
AU - Dingli, D.
AU - Gertz, M. A.
AU - Kyle, R. A.
AU - Greipp, P. R.
AU - Rajkumar, S. V.
AU - Witzig, T. E.
N1 - Funding Information: Shaji Kumar receives research support for clinical trials from Celgene, Novartis, Millennium, Bayer, Genzyme, Merck and Cephalon. Angela Dispenzieri and Martha Q Lacy receive research funding from Celgene. Philip R. Greipp receives research funding grants from Celgene and Novartis, and is on the advisory board of Amgen. Morie A Gertz receives research support from Millennium and Novartis, and honorarium from Celgene and Millennium. Robert A Kyle has been on the disease and/or data monitoring committees of Celgene, Novartis, Merck, Bristol-Myers Squibb Keryx Biopharmaceuticals, Onyx Pharmaceuticals and Johnson and Johnson sponsored studies. He is also a consultant for Millennium and receives honoraria from Binding Site. Thomas E Witzig receives research support from Celgene and Novartis. He has participated in Celgene advisory boards of Celgene, but has deferred the honorarium to Mayo Clinic, Rochester, MN, USA. The remaining authors declare no conflict of interest. Funding Information: This study is supported in part by the grants CA 62242, CA 107476 and CA 62242 from the National Cancer Institute, National Institutes of Health, Bethesda, MD and the Eastern Cooperative Oncology Group, Boston, MA (SVR).
PY - 2011/7
Y1 - 2011/7
UR - http://www.scopus.com/inward/record.url?scp=79960226207&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79960226207&partnerID=8YFLogxK
U2 - 10.1038/leu.2011.54
DO - 10.1038/leu.2011.54
M3 - Article
C2 - 21468037
AN - SCOPUS:79960226207
VL - 25
SP - 1195
EP - 1197
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - 7
ER -